# A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a

Source: https://onco.cc/trials/nct04280081/  
OnCo record `nct04280081` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Selpercatinib in thyroid cancer, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation is a phase 2 interventional study registered as NCT04280081 by Eli Lilly and Company, with 77 participants enrolled, started 2020-03-16 and due to reach its primary completion in 2021-03-25. Interventions recorded: Selpercatinib. Conditions listed: Solid Tumor, Medullary Thyroid Cancer. Results were posted on ClinicalTrials.gov in 2022; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: LIBRETTO-321
- Tags: ctgov-ingest
- Registry id: NCT04280081
- Phase: 2
- Setting: A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
- Sponsor: Eli Lilly and Company
- Enrolled: 77
- Outcomes: Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC), Overall Response (CR/PR): RET Fusion Positive Non-small Cell Lung Cancer (NSCLC) Cohort 1 69.2% vs RET Fusion Positive Thyroid Cancer (TC) Cohort 1 100% vs RET Mutant Medullary Thyroid Cancer (MTC) Cohort 2 57.7%; Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC, Overall Response (CR/PR): Non-small Cell Lung Cancer (All NSCLC) 66% vs Thyroid Cancer (All TC) 100% vs Medullary Thyroid Cancer (All MTC) 58.6%

## Sources

- ClinicalTrials.gov NCT04280081: https://clinicaltrials.gov/study/NCT04280081

## Connected records

- cancers: [Medullary thyroid cancer](https://onco.cc/cancers/medullary-thyroid-cancer/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Selpercatinib](https://onco.cc/drugs/selpercatinib/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct04280081.json